Pfizer Inc.
$673.7M 570,295 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation reported $676,046,921.08 across General Payments, Research, and Ownership to 411,238 physicians and teaching hospitals across 418,352 transactions.
- $676.0M
- All-tracks total
- 418,352
- Transactions
- 411,238
- Recipients
- +$2.0M
- General Payments vs PY2023
Novartis Pharmaceuticals Corporation reported $676,046,921.08 across all CMS Open Payments tracks (General + Research + Ownership) to 411,238 physicians and teaching hospitals in Program Year 2024 - ranking #1 of 1,925 reporting manufacturers (4.9% of the all-tracks industry total); General Payments alone were $19,710,992.43, averaging $1.6K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer novartis-pharmaceuticals-corporation Novartis Pharmaceuticals Corporation
$676.0M · #1/1,925 · 4.9% industry · PY2024
- TOT $676.0M
- RANK #1
- SHARE 4.9%
- TXN 418,352
- RCP 411,238
- CAT 8
- GEN $19.7M
- ΔGEN +$2.0M
- TOP1 6.6%
- PY 2024
Volume peers
Nearest volume peer: Pfizer Inc. ($673.7M)
Novartis Pharmaceuticals Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Novartis Pharmaceuticals Corporation's CMS-reported General Payments increased by $2.0M (+11.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOVARTIS PHARMACEUTICALS CORPORATIONPY2023: NOVARTIS PHARMACEUTICALS CORPORATIONPY2024: Novartis Pharmaceuticals Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $17,691,929.47
- PY2024
- $19,710,992.43
What the Data Shows for Novartis Pharmaceuticals Corporation
Rank #1 of 1,925 companies in CMS Open Payments for 2024 belongs to Novartis Pharmaceuticals Corporation, which reported $676,046,921.08 across 418,352 transactions to 411,238 recipients - a top-tier 4.9% share of all industry payments reported nationwide for the year. Averages work out to $1.6K per transaction and $1.6K per recipient.
The 8-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $7.8M, accounting for 39.7% of this company's General Payments and 400,116 transactions.
General Payment Breakdown by Type
Novartis Pharmaceuticals Corporation made 8 types of general payments. "Food and Beverage" is the largest category at $7.8M, 39.7% of General Payments.
Novartis Pharmaceuticals Corporation reports 8 general-payment categories - the top three are Food and Beverage (39.7%), Consulting Fee (25.0%), and Compensation for Services Other Than Consulting (22.3%). The remaining 5 categories make up 13.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Novartis Pharmaceuticals Corporation files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Novartis Pharmaceuticals Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $7.8M | 400,116 | 39.7% |
| Consulting Fee | $4.9M | 1,533 | 25.0% |
| Compensation for Services Other Than Consulting | $4.4M | 487 | 22.3% |
| Grant | $726.8K | 42 | 3.7% |
| Long-Term Medical Supply or Device Loan | $652.8K | 6,952 | 3.3% |
| Travel and Lodging | $623.0K | 1,834 | 3.2% |
| Space Rental or Facility Fees | $558.5K | 207 | 2.8% |
| Education | $900.48 | 67 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,328,149.24 (16.9%) of $19,710,992.43 in this company's General Payments records across 84,903 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Novartis Pharmaceuticals Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Szilard Voros
$1,300,132.35 across 5 reported transactions
- 2
Cleveland Clinic Hospital
$783,800.00 across 17 reported transactions
- 3
Dana-Farber Cancer Institute
$636,352.00 across 4 reported transactions
- 4
Strong Memorial Hospital
$359,995.83 across 7 reported transactions
- 5
Brigham And Womens Hospital
$247,869.06 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Novartis Pharmaceuticals Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Novartis Pharmaceuticals Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Novartis Pharmaceuticals Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
ModernaTX, Inc.
$665.3M 3,173 recipients
Compare payment profiles
Eli Lilly and Company
$652.4M 8,748 recipients
Compare payment profiles
Abbvie Inc.
$607.8M 1,721,235 recipients
Compare payment profiles
Merck Sharp & Dohme LLC
$525.2M 216,602 recipients
Compare payment profiles
AstraZeneca Pharmaceuticals LP
$428.2M 858,609 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.